Cybin Inc (HELP) Stock Forecast & Price Target

Helus Pharma is a clinical-stage neuropsychiatry company with a diverse pipeline of novel serotonergic agonists targeting mental health disorders such as depression and anxiety. With enrollment completed in the Phase 3 clinical trial for their lead asset HLP003, investors can expect to see topline data by mid-November, increasing confidence in the company's potential. Additionally, Helus' second asset, HLP004, has shown promising results in a Phase 2a study for generalized anxiety disorder and is expected to enter a Phase 2b trial by the end of 3Q26. With a strong management team, a growing interest in psychedelics in the pharmaceutical industry, and potential blockbuster revenue projections of $5.5 billion, Helus Pharma is poised for success.

Helus Pharma is a clinical-stage biotechnology company with a reinforced balance sheet and early-stage pipeline progress, but its market valuation will heavily depend on the success of its pipeline candidates in clinical development for the treatment of mental health conditions. In the event of failed clinical trials, increased competition, or difficulty securing funding, the company's stock may not meet projected financial expectations. Additionally, the efficacy of HLP003, the first Phase 3 adjunctive readout in its class, remains to be seen and will play a key role in determining the company's future success. The change in reporting currency since F1Q26 may also impact past financials and should be considered when evaluating the company's overall financial health.